Cardioprotective properties of sevoflurane in patients undergoing coronary surgery with cardiopulmonary bypass are related to the modalities of its administration.
BACKGROUND
Experimental studies have related the cardioprotective effects of sevoflurane both to preconditioning properties and to beneficial effects during reperfusion. In clinical studies, the cardioprotective effects of volatile agents seem more important when administered throughout the procedure than when used only in the preconditioning period. The authors hypothesized that the cardioprotective effects of sevoflurane observed in patients undergoing coronary surgery with cardiopulmonary bypass are related to timing and duration of its administration.


METHODS
Elective coronary surgery patients were randomly assigned to four different anesthetic protocols (n = 50 each). In a first group, patients received a propofol based intravenous regimen (propofol group). In a second group, propofol was replaced by sevoflurane from sternotomy until the start of cardiopulmonary bypass (SEVO pre group). In a third group, propofol was replaced by sevoflurane after completion of the coronary anastomoses (SEVO post group). In a fourth group, propofol was administered until sternotomy and then replaced by sevoflurane for the remaining of the operation (SEVO all group). Postoperative concentrations of cardiac troponin I were followed during 48 h. Cardiac function was assessed perioperatively and during 24 h postoperatively.


RESULTS
Postoperative troponin I concentrations in the SEVO all group were lower than in the propofol group. Stroke volume decreased transiently after cardiopulmonary bypass in the propofol group but remained unchanged throughout in the SEVO all group. In the SEVO pre and SEVO post groups, stroke volume also decreased after cardiopulmonary bypass but returned earlier to baseline values than in the propofol group. Duration of stay in the intensive care unit was lower in the SEVO all group than in the propofol group.


CONCLUSIONS
In patients undergoing coronary artery surgery with cardiopulmonary bypass, the cardioprotective effects of sevoflurane were clinically most apparent when it was administered throughout the operation.
De Hert
Stefan G
SG
Division of Cardiothoracic and Vascular Anesthesia, University Hospital Antwerp. stefan.dehert@ua.ac.be
Van der Linden
Philippe J
PJ
Cromheecke
Stefanie
S
Meeus
Roel
R
Nelis
Anne
A
Van Reeth
Veronique
V
ten Broecke
Pieter W
PW
De Blier
Ivo G
IG
Stockman
Bernard A
BA
Rodrigus
Inez E
IE
D000368:Aged; D000769:Anesthesia, Inhalation; D000771:Anesthesia, Intravenous; D018685:Anesthetics, Inhalation / Q000008:administration & dosage / Q000627:therapeutic use*; D018686:Anesthetics, Intravenous; D006348:Cardiac Surgical Procedures; D002315:Cardiopulmonary Bypass / Q000009:adverse effects*; D003331:Coronary Vessels / Q000601:surgery; D003401:Creatine / Q000097:blood; D005260:Female; D006331:Heart Diseases / Q000517:prevention & control*; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D019157:Ischemic Preconditioning, Myocardial; D008297:Male; D008738:Methyl Ethers / Q000008:administration & dosage / Q000627:therapeutic use*; D008875:Middle Aged; D009206:Myocardium / Q000378:metabolism; D015742:Propofol; D011446:Prospective Studies; D000077149:Sevoflurane; D013997:Time Factors; D019210:Troponin I / Q000378:metabolism; D016277:Ventricular Function, Left / Q000187:drug effects
D018685:Anesthetics, Inhalation; D018686:Anesthetics, Intravenous; D008738:Methyl Ethers; D019210:Troponin I; D000077149:Sevoflurane; D003401:Creatine; D015742:Propofol